Skip to main content
SpringerLink
Log in

Adjuvant or Salvage Radiotherapy in Postoperative Prostate Cancer

  • Chapter
  • First Online:
Principles and Practice of Urooncology

  • 1090 Accesses

Abstract

Prostate-specific antigen (PSA) screening increased the diagnosis of prostate cancer at a localized stage to be treated with a curative intent; approximately half of them undergo radical prostatectomy, and roughly one third of surgically treated patients are expected to experience a recurrence in 10 years’ follow-up. Once PSA failure occurs, many develop distant metastases at a median of 8 years and afterward followed by cancer-related death at a median of 5 years. Biochemical failure risk after radical prostatectomy is mainly expected mostly in men with any of the following features: detectable postoperative PSA, positive surgical margins , extraprostatic extension of tumor (T3a), seminal vesicle invasion (T3b), and Gleason score ≥ 8. The radiotherapy in the undetectable PSA environment (<0.01 ng/mL) within 4 months after prostatectomy is termed as “adjuvant, ” while radiotherapy in rising PSA within any time after prostatectomy is defined as “salvage. ”

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Cancer Society: Cancer Facts & Figures. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

    Article  PubMed  Google Scholar 

  3. Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, Klein E, Michalski J, Roach M, Sartor O, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline. J Urol. 2013;190(2):441–9.

    Article  PubMed  Google Scholar 

  4. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997;24(2):395–406.

    Article  CAS  PubMed  Google Scholar 

  5. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–7.

    Article  CAS  PubMed  Google Scholar 

  6. Moreira DM, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol. 2009;182(5):2250–5.

    Article  PubMed  Google Scholar 

  7. Moreira DM, Jayachandran J, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Stephenson AJ, Freedland SJ. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the search database. BJU Int. 2009;104(10):1452–6.

    Article  PubMed  Google Scholar 

  8. Freedland SJ, Rumble RB, Finelli A, Chen RC, Slovin S, Stein MN, Mendelson DS, Wackett C, Sandler HM. Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(34):3892–8.

    Article  Google Scholar 

  9. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291(11):1325–32.

    Article  CAS  PubMed  Google Scholar 

  10. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008;299(23):2760–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. 2016.

    Google Scholar 

  12. Connolly JA, Shinohara K, Presti JC Jr, Carroll PR. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology. 1996;47(2):225–31.

    Article  CAS  PubMed  Google Scholar 

  13. Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology. 2001;219(2):432–9.

    Article  CAS  PubMed  Google Scholar 

  14. Cotter SE, Chen MH, Moul JW, Lee WR, Koontz BF, Anscher MS, Robertson CN, Walther PJ, Polascik TJ, D’Amico AV. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer. 2011;117(17):3925–32.

    Article  PubMed  Google Scholar 

  15. Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296(19):2329–35.

    Article  CAS  PubMed  Google Scholar 

  16. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3):956–62.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366(9485):572–8.

    Article  Google Scholar 

  18. Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380(9858):2018–27.

    Article  PubMed  Google Scholar 

  19. Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, Storkel S, Willich N, Semjonow A, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014;66(2):243–50.

    Article  PubMed  Google Scholar 

  20. Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stockle M, Rube C, Semjonow A, Wirth M, Storkel S, et al. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. Int J Radiat Oncol Biol Phys. 2015;91(2):288–94.

    Article  PubMed  Google Scholar 

  21. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, Willich N, Semjonow A, Souchon R, Stockle M, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(18):2924–30.

    Article  Google Scholar 

  22. Valicenti RK, Thompson I Jr, Albertsen P, Davis BJ, Goldenberg SL, Wolf JS, Sartor O, Klein E, Hahn C, Michalski J, et al. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys. 2013;86(5):822–8.

    Article  PubMed  Google Scholar 

  23. Parker C, Sydes MR, Catton C, Kynaston H, Logue J, Murphy C, Morgan RC, Mellon K, Morash C, Parulekar W, et al. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int. 2007;99(6):1376–9.

    Article  PubMed  Google Scholar 

  24. Taneja SS. Re: a phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy-Adjuvant Versus Early Salvage (RAVES) trial. J Urol. 2015;193(2):539.

    Article  Google Scholar 

  25. Pearse M, Fraser-Browne C, Davis ID, Duchesne GM, Fisher R, Frydenberg M, Haworth A, Jose C, Joseph DJ, Lim TS, et al. A phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy—Adjuvant Versus Early Salvage (RAVES) trial. BJU Int. 2014;113(Suppl 2):7–12.

    Article  PubMed  Google Scholar 

  26. Nguyen PL. Value of extra-early initiation of salvage radiation for increasing prostate-specific antigen after prostatectomy. J Clin Oncol Off J Am Soc Clin Oncol. 2016.

    Google Scholar 

  27. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(15):2035–41.

    Article  Google Scholar 

  28. King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys. 2012;84(1):104–11.

    Article  PubMed  Google Scholar 

  29. Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, et al. Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy. Eur Urol. 2016;69(4):728–33.

    Article  PubMed  Google Scholar 

  30. Mir MC, Li J, Klink JC, Kattan MW, Klein EA, Stephenson AJ. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur Urol. 2014;66(2):204–10.

    Article  PubMed  Google Scholar 

  31. Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, Dicker AP, Lallas CD, Gomella LG, Davicioni E, et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(8):944–51.

    Article  Google Scholar 

  32. Perrapato SD, Gore J, du Plessis M, Santiago-Jimenez M, Yousefi K, Thompson D, Chen D, Clark W, Franks M, Karsh L, et al. A genomic classifier impacts adjuvant treatment decision making among patients with high-risk pathology at radical prostatectomy: results from the multicenter prospective PRO-IMPACT study. Int J Radiat Oncol Biol Phys. 2016;96(2S):S104.

    Article  Google Scholar 

  33. Klein EA, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson AJ, Li J, Kattan MW, Magi-Galluzzi C, Davicioni E. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol. 2015;67(4):778–86.

    Article  PubMed  Google Scholar 

  34. Freedland SJ, Choeurng V, Howard L, De Hoedt A, du Plessis M, Yousefi K, Lam LL, Buerki C, Ra S, Robbins B, et al. Utilization of a genomic classifier for prediction of metastasis following salvage radiation therapy after radical prostatectomy. Eur Urol. 2016.

    Google Scholar 

  35. King CR. Adjuvant radiotherapy after prostatectomy: does waiting for a detectable prostate-specific antigen level make sense? Int J Radiat Oncol Biol Phys. 2011;80(1):1–3.

    Article  PubMed  Google Scholar 

  36. Cheung R, Kamat AM, de Crevoisier R, Allen PK, Lee AK, Tucker SL, Pisters L, Babaian RJ, Kuban D. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys. 2005;63(1):134–40.

    Article  PubMed  Google Scholar 

  37. Kurokawa K, Ito K, Suzuki K, Ono Y, Yamamoto T, Akimoto T, Yamanaka H. Salvage external beam radiotherapy for local recurrence without systemic progression or prostate specific antigen recurrence of prostate cancer after initial hormonal therapy: is it possible to identify patients likely to have good treatment outcomes? Jpn J Clin Oncol. 2002;32(11):466–71.

    Article  PubMed  Google Scholar 

  38. Spiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys. 2007;69(1):54–61.

    Article  PubMed  Google Scholar 

  39. Ost P, Cozzarini C, De Meerleer G, Fiorino C, De Potter B, Briganti A, Nagler EV, Montorsi F, Fonteyne V, Di Muzio N. High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2012;83(3):960–5.

    Article  PubMed  Google Scholar 

  40. Shipley WU, Hunt D, Lukka HR, Major P, Heney NM, Grignon D, Patel M, Bahary J, Lawton CA, Sandler HM. Initial report of RTOG 9601, a phase III trial in prostate cancer: effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(7_suppl):1.

    Article  Google Scholar 

  41. Shipley WU, Hunt D, Lukka HR, Major P, Heney NM, Grignon D, Patel M, Bahary J, Lawton CA, Sandler HM. Report of NRG Oncology/RTOG 9601, a phase III trial in prostate cancer: anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) in patients following radical prostatectomy (RP) with pT2–3pN0 disease and an elevated PSA. Presented at the 2015 Annual Meeting of the American Society for Radiation Oncology, San Antonio, TX (Late Breaking Abstract 5). 2015.

    Google Scholar 

  42. Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL, Beckendorf V, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016;17(6):747–56.

    Article  CAS  PubMed  Google Scholar 

  43. Prostate Post-Op RTOG Atlas. https://www.rtog.org/CoreLab/ContouringAtlases/ProstatePostOp.aspx

  44. Michalski JM, Lawton C, El Naqa I, Ritter M, O’Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;76(2):361–8.

    Article  PubMed  Google Scholar 

  45. Croke J, Maclean J, Nyiri B, Li Y, Malone K, Avruch L, Kayser C, Malone S. Proposal of a post-prostatectomy clinical target volume based on pre-operative MRI: volumetric and dosimetric comparison to the RTOG guidelines. Radiat Oncol. 2014;9:303.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Wang J, Kudchadker R, Choi S, Pettaway CA, Choi H, Hobbs BD, Occena MC, McGuire SE, Pugh TJ, Hoffman K, et al. Local recurrence map to guide target volume delineation after radical prostatectomy. Pract Radiat Oncol. 2014;4(6):e239–46.

    Article  PubMed  Google Scholar 

  47. van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, Nguyen Q, Ho B, Emmett L. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int. 2016;117(5):732–9.

    Article  PubMed  Google Scholar 

  48. Ohri N, Dicker AP, Trabulsi EJ, Showalter TN. Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer. 2012;48(6):837–44.

    Article  PubMed  Google Scholar 

  49. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(16):2225–9.

    Article  Google Scholar 

  50. King CR. The dose-response of salvage radiation therapy following radical prostatectomy: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2016;96(2S):S101–2.

    Article  Google Scholar 

  51. Hegarty SE, Hyslop T, Dicker AP, Showalter TN. Radiation therapy after radical prostatectomy for prostate cancer: evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort. PLoS One. 2015;10(2):e0118430.

    Article  PubMed  PubMed Central  Google Scholar 

  52. van Stam MA, Aaronson NK, Pos FJ, Bosch JL, Kieffer JM, Tillier CN, van der Poel HG. The effect of salvage radiotherapy and its timing on the health-related quality of life of prostate cancer patients. Eur Urol. 2016;70(5):751–7.

    Article  PubMed  Google Scholar 

  53. Zaffuto E, Gandaglia G, Fossati N, Dell’Oglio P, Moschini M, Cucchiara V, Suardi N, Mirone V, Bandini M, Shariat SF, et al. Early postoperative radiotherapy is associated with worse functional outcomes in patients with prostate cancer. J Urol. 2016;197(3 Pt 1):669–75.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Koc University, Istanbul, Turkey

    Ugur Selek M.D. & Yasemin Bolukbasi M.D.

  2. Department of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

    Ugur Selek M.D., Yasemin Bolukbasi M.D. & Deborah A. Kuban M.D., F.A.C.R., F.A.S.T.R.O.

Authors
  1. Ugur Selek M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasemin Bolukbasi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Deborah A. Kuban M.D., F.A.C.R., F.A.S.T.R.O.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deborah A. Kuban M.D., F.A.C.R., F.A.S.T.R.O. .

Editor information

Editors and Affiliations

  1. Chair and Professor, Department of Radiation Oncology, Hacettepe University, Ankara, Turkey

    Gokhan Ozyigit

  2. Chair and Professor, Department of Radiation Oncology, Koc University, Istanbul, Turkey

    Ugur Selek

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Selek, U., Bolukbasi, Y., Kuban, D.A. (2017). Adjuvant or Salvage Radiotherapy in Postoperative Prostate Cancer. In: Ozyigit, G., Selek, U. (eds) Principles and Practice of Urooncology. Springer, Cham. https://doi.org/10.1007/978-3-319-56114-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56114-1_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56113-4

  • Online ISBN: 978-3-319-56114-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation